Vimizim

Indicated For

Mucopolysaccharidosis IVA (MPS IVA)

About This Medication

# BioMarin Vimizim Patient Assistance Program Guide: How to Get Vimizim (elosulfase alfa) at Low or No Cost Vimizim (elosulfase alfa) is a vital enzyme replacement therapy for patients with **Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome)**, a rare genetic disorder that affects bone, cartilage, and connective tissue development. This patient-friendly guide explains BioMarin's patient assistance program (often called BioMarin Access™ or similar), designed to help eligible patients access Vimizim at little to no cost, especially if you face financial or insurance barriers.[1][2][4] ## About Vimizim and Morquio A Syndrome **Vimizim** is an intravenous enzyme therapy that provides the missing enzyme N-acetylgalactosamine-6-sulfatase, helping break down harmful glycosaminoglycans (GAGs) that build up in cells due to MPS IVA. Administered weekly at a dose of **2 mg per kg body weight** over 3.5 to 4.5 hours (depending on weight), it must be given under medical supervision due to risks like anaphylaxis (severe allergic reactions with symptoms such as cough, rash, or throat swelling).[1][2][4] Morquio A syndrome typically causes short stature, skeletal abnormalities, joint issues, breathing problems, and mobility challenges. Early treatment with Vimizim can improve endurance, growth, and quality of life, but lifelong weekly infusions are usually needed. Always discuss risks, including hypersensitivity reactions, with your doctor.[2][3] ## Who Qualifies for the Program? BioMarin's assistance programs, like BioMarin Access, target U.S. residents with MPS IVA who need Vimizim but can't afford it due to income, lack of insurance, or coverage gaps. Key eligibility factors include: - Confirmed diagnosis of MPS IVA. - U.S. citizenship or legal residency. - Financial need based on **Federal Poverty Level (FPL)** guidelines (typically up to 400-500% FPL, though exact thresholds vary; contact program for current details). - Under commercial insurance, Medicare, Medicaid, or uninsured status (with restrictions).[1][4] Programs often provide free medication, infusion support, copay assistance (up to $15,000/year for eligible insured patients), or free drug for uninsured/low-income patients. ## Income Eligibility Breakdown Eligibility hinges on household income relative to FPL. While specific Vimizim thresholds aren't publicly detailed in all sources, BioMarin programs generally follow these common PAP guidelines (confirm with program as they update annually): | Household Size | Up to 400% FPL (Free Drug) | Up to 500% FPL (Copay Help) | |----------------|----------------------------|-----------------------------| | 1 (Individual) | $60,320 | $75,400 | | 2 (Couple) | $81,760 | $102,200 | | 3 | $103,280 | $129,000 | | 4 | $124,800 | $156,000 | *Add ~$21,520 per person for larger families at 400% FPL. Assets may be reviewed. Medicare Part D patients often ineligible for free drug but may get copay aid.*[4] ## Insurance Requirements - **Commercial insurance**: Eligible for copay cards or free drug if high out-of-pocket costs. - **Medicare/Medicaid**: Limited free drug access; copay assistance available but not for government insurance in some cases. - **Uninsured**: Primary target for full free supply. Your doctor's office verifies insurance. Prior authorization (PA) from your insurer is usually required, including diagnosis proof and dosing details.[4] ## Step-by-Step Application Process 1. **Consult your doctor**: Confirm MPS IVA diagnosis and Vimizim prescription. Discuss infusion site options.[2] 2. **Contact BioMarin Access**: Call **1-866-906-6100** (general BioMarin support line; ask for Vimizim PAP) or visit **www.biomarinaccess.com** to start.[4] 3. **Gather documents**: - Proof of income (tax returns, pay stubs, W-2s for past 1-2 months). - Insurance card/ID. - Prescription and medical records (diagnosis, weight for dosing). - Photo ID and SSN (last 4 digits).[1] 4. **Submit application**: Online portal, fax, or mail. Doctor completes clinical sections. 5. **Approval wait**: 1-4 weeks; expedited for urgent cases. 6. **Receive benefits**: Drug shipped to infusion center or home (if applicable).[4] ## Timeline and Delivery - **Processing**: 5-10 business days standard; up to 30 days if complex. - **Delivery**: Vimizim is refrigerated and shipped overnight to your approved infusion center (hospital, clinic, or specialty pharmacy). Home infusion rare due to monitoring needs. Infusions scheduled weekly post-delivery.[2][4] - **Refills**: Automatic if reauthorized; notify program of changes. ## Alternatives if Denied or Ineligible - **Appeal denial**: Submit additional income/insurance proof within 30 days. - **Other PAPs**: NeedyMeds.org or PAN Foundation for MPS grants. - **State programs**: Check Medicaid waivers for rare diseases. - **Clinical trials**: Search ClinicalTrials.gov for Vimizim studies. - **Biosimilars**: None currently available.[1][3] - **Financial aid**: 501(c)(3) charities like Morquio Syndrome organizations. ## Important Disclaimer This guide provides general information based on available sources as of 2026 and is not official advice. Program details change; **always verify with BioMarin Access at 1-866-906-6100 or biomarinaccess.com**. Eligibility not guaranteed. Consult your healthcare provider for personalized guidance. Vimizim carries serious risks like anaphylaxis—treatment requires medical oversight. BioMarin disclaims liability for third-party info.

Program information last verified: March 30, 2026